Genomic characterization of cervical cancer based on human papillomavirus status
GYNECOLOGIC ONCOLOGY
Authors: Zhang, Liya; Jiang, Yi; Lu, Xiaofan; Zhao, Huiling; Chen, Chen; Wang, Yaoyan; Hu, Wenjun; Zhu, Yue; Yan, Hangyu; Yan, Fangrong
Abstract
Objective. It is uncommon for cervical cancer patients to be diagnosed without a human papillomavirus (HPV) infection. As prophylactic vaccines against high-risk HPV types are an ineffective preventive measure for these patients it is essential to identify differential biomarkers that may be associated with detection, prognosis and novel targeted therapies. The objective of this study was to compare the two entities, HPV+ and HPV- cervical cancers, based on TCGA public data. Methods. We collected and analyzed clinical information of 299 cervical cancer patients as the first step, then identified differential expressed genes and conducted downstream analyses to characterize this tumor based on HPV status, including functional annotation, pathway mapping, survival analysis and comparative somatic mutation landscapes. We further inferred the likelihood of responding to traditional treatment including radiotherapy and chemotherapy. Results. It was found that HPV tumors were likely to occur at an older age and were often adenocarcinomas or adenosquamous carcinomas, and there was no significant overall survival difference between HPV+ vs. HPV- tumors. Gene expression profiles of HPV+ and HPV- tumors differed especially in ANKRD7, SERPINB3, EMX2, MEI], RNF212, RP11-13 K12.5, RP11-325E222 and ZFR2 which were significantly relevant to cervical cancer prognosis. TP53, ARID5B,ARID1A, CTNNB1 and PTEN were significantly differentially mutated between HPV+ and HPV tumors. Results of radiotherapy analyses demonstrated that CDO1, PCDHB2 and MYOD1 were different between the two subsets. In addition, RP11-299 L17.3, SLC14A2, FGF18 and OASL represented different drug sensitivity to cisplatin between both. Conclusions. These potential biomarkers may offer insights to further personalize therapeutic decision making to improve survival in HPV- cervical cancer patients. (C) 2018 Elsevier Inc. All rights reserved.
Embryonal Rhabdomyosarcoma of the Oral Cavity
HEAD & NECK PATHOLOGY
Authors: McInturff, Mark; Adamson, Anne; Donaldson, Chadwick; Nelson, Brenda L.
Abstract
A 19 year old female presents to the emergency room with right facial enlargement. Clinical examination revealed a soft tissue mass of the right buccalmucosa. Treated initially as infection, the patient later turned to clinic with now rapidly enlarging and intermittently painful mass. Computed tomography with contrast showed a low attenuated buccal mass with mild enhancement lateral to the right caudal maxilla and superior mandible. Biopsy was performed and microscopic examination showed cells with moderate pleomorphism with numerous atypical mitotic figures and occasional elongated "strap" cells with eccentric nuclei. Fluorescence in situ hybridization analysis revealed no rearrangement of the FKHR gene. The diagnosis of embryonal rhabdomyosarcoma was rendered. The patient was referred to the local children's hospital for definitive treatment.